Stocks
MoonLake’s Sonelokimab Faces Regulatory, Commercial Tests, RBC Says
MoonLake Immunotherapeutics' investigational drug, sonelokimab, is reportedly facing significant regulatory and commercial scrutiny, according to analysis by RBC.
#sonelokimab 2 articles
Stocks
MoonLake Readies FDA Filing for Skin Treatment Sonelokimab
MoonLake Immunotherapeutics (MLTX) reported strong one-year Phase 3 trial results for sonelokimab in hidradenitis suppurativa, planning a U.S. FDA filing this fall.